ArthroCare Sews Up an Advantage in Sports Medicine

In a rapidly growing market like the sports medicine segment of orthopedics, it pays for companies to strike early. The introduction of new technologies and a population that alternates between sedentary work weeks and extreme sports on the weekends are fueling market growth rates of 30% annually. Thus, ArthroCare Corp. didn't hesitate to snap up five-year-old Opus Medical Inc., developer of a novel suturing and anchor system for arthroscopic soft tissue repair. In sports medicine, AthroCare's largest and most established target market (spine and ear, nose & throat are its other major markets), the Opus technology will help ArthroCare increase market penetration.

In a rapidly growing market like the sports medicine segment of orthopedics, it pays for companies to strike early. The introduction of new technologies and a population that alternates between sedentary work weeks and extreme sports on the weekends are fueling market growth rates of 30% annually. The American Association of Orthopedic Surgeons estimates that approximately 11% of all injuries—things like fractures, dislocations, and tears to the knees and shoulders--are related to sports, to the tune of 6.6 million such injuries each year. Three-quarters of these patients are under the age of 65. An increase in the number of aging and active people is bound to contribute to the growing number of injuries. Thus, ArthroCare Corp. didn't hesitate to snap up five-year-old Opus Medical Inc. for $130 million in a combination of cash and stock, plus earn-outs based on sales thresholds. [See Deal] Indeed, says ArthroCare president Michael Baker, the company has been in discussions with Opus for a year.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Merck’s Digital Biomarker Strategy For Commercial Gains In Neurology

 
• By 

The integration of digital health tools into clinical research and patient care is gaining momentum, and Merck KGaA, Darmstadt, Germany is not letting the grass grow under its feet. With an approach to digital biomarkers, the company is seeking to redefine how neurological diseases are monitored and managed.

Rising Leaders 2025: Gunnar Sachs On Pursuing The Legal Path To Life Science Business Growth

 
• By 

Not everyone welcomes change as much as lawyers do. There is much of that ahead for Clifford Chance partner and life science expert Gunnar Sachs as he negotiates political shifts and surfs the rising tide of legal challenges to help companies stay compliant and competitive. Musicianship provides the work-life balance.

Podcast: iOnctura’s Mission To Treat Rare Cancers With Precision Therapies

 
• By 

In Vivo spoke with Catherine Pickering, the CEO and founder of iOnctura, a UK-based clinical stage biotech company developing therapies for uveal melanoma and other hard-to-treat cancers by disrupting the tumor-stroma-immune interface.